Google DeepMind launches Gemini for Science at I/O with two Nature papers published same day, AI beats CDC COVID forecasting model

Started by Aaron, May 21, 2026, 12:16 PM

Previous topic - Next topic

0 Members and 1 Guest are viewing this topic.

Topic: Google DeepMind launches Gemini for Science at I/O with two Nature papers published same day, AI beats CDC COVID forecasting model   Views(Read 66 times)

Aaron

Google DeepMind launched Gemini for Science on May 19th at I/O 2026, backed by something rare in AI product announcements: peer-reviewed validation published in Nature on the same day. Two papers, one on Co-Scientist and one on Empirical Research Assistance, dropped simultaneously. ERA outperformed the US Centers for Disease Control and Prevention's own COVID-19 hospitalisation forecasting ensemble.

The suite bundles three tools targeting distinct research phases. Hypothesis Generation uses a multi-agent idea tournament where AI agents generate, debate, and score competing hypotheses with clickable citations for every claim. Co-Scientist helped Stanford Medicine researchers identify Vorinostat, an existing anti-cancer drug, as a candidate for liver fibrosis treatment, reducing TGFβ-induced chromatin changes by 91 percent in hepatic organoid tests. Computational Discovery, built on AlphaEvolve and ERA, runs thousands of code variations in parallel.

Gemini for Science: AI experiments and tools for a new era of discovery

IronQuarry48

Same-day Nature publication alongside a product launch is an unusual move that significantly raises the credibility bar. Most AI-for-science announcements are press releases with zero peer review attached
Posted from a machine that definitely needs a clean install

KeyboardWarrior

The Vorinostat liver fibrosis result is genuinely interesting because it is an FDA-approved drug with a known safety profile. Identifying a new therapeutic application rather than proposing a novel compound accelerates the path to clinical validation enormously
Press F to pay respects

Beth3.0

Beating the CDC forecasting ensemble is a specific and verifiable benchmark. I want to see the methodology for that comparison before getting too excited but the specificity is encouraging

Plateau65

The idea tournament format for hypothesis generation is the right design. Having agents argue against each other before surfacing a result is a better epistemic architecture than a single model generating unchallenged outputs
Measure twice, post once

Glenn_44

91 percent reduction in TGFβ-induced chromatin changes in organoid tests is a striking figure. Organoid tests are not the same as clinical trials but this is a meaningful step beyond pure in-silico prediction

Phil95

The AlphaEvolve integration into Computational Discovery is the part that makes this a research acceleration tool rather than a literature search tool. Generating and testing code variations at scale is genuinely different from what researchers could do manually

Connor97

The clickable citations claim is the one I am most cautious about. Citation verification in AI systems has a poor track record. If this actually works at the claimed standard it is the most important feature in the suite

Oscar_57

Google being able to publish Nature papers on the same day as a product launch is a function of their research firepower. Most companies cannot do that. It matters for how seriously this will be taken in the scientific community
rm -rf /bad-ideas

Cass82

The CDC forecasting comparison will need independent replication. A lab testing their own system against a specific benchmark they chose is not the same as independent evaluation

Related Topics (6)